Viscosupplementation Market Size, Share & Forecast Report - 2026 to 2030

The global viscosupplementation market size was valued at around USD 5 billion in 2024 and expected to grow at a significant CAGR of over 6% during the forecast period from 2025 to 2030. The rising demand for osteoarthritis treatment and the increasing prevalence of lifestyle-related disorders are some major factors to drive the market growth. Furthermore, the rapid growth in geriatric population and increasing rate of osteoarthritis is expected to fuel the market over the forecast period. According to the latest information shared by NIH, around 13% of women and 10% of men aged 60 and more years are suffered from osteoarthritis.

Market Outlook:

Industry Trends Shaping the Viscosupplementation Market:

The viscosupplementation market is witnessing steady growth, primarily driven by the rising prevalence of osteoarthritis and the growing aging population worldwide. A key trend is the increasing preference for minimally invasive treatments over surgical interventions, as patients and healthcare providers seek therapies that provide pain relief, improve mobility, and delay the need for joint replacement surgeries. Single-injection formulations are gaining popularity due to better patient compliance and reduced treatment costs, compared to traditional multi-injection regimens. Additionally, the expanding use of viscosupplementation in younger patients with sports injuries or early-stage osteoarthritis is widening the market’s application base.

Another notable trend is the ongoing innovation in hyaluronic acid (HA) formulations used for viscosupplementation. Companies are focusing on developing cross-linked and high-molecular-weight HA products that offer longer-lasting efficacy and reduced side effects. Alongside, the adoption of image-guided injections for improved accuracy and outcomes is becoming more common in clinical practice. North America currently dominates the market due to high awareness, established reimbursement systems, and advanced healthcare infrastructure, while the Asia-Pacific region is emerging as a fast-growing market owing to its large patient pool and rising healthcare expenditure. Overall, advancements in formulation technology and growing patient demand for non-surgical treatment options are shaping the evolution of the viscosupplementation market.

Viscosupplementation Market Driving Factors:

• Increasing Prevalence of Osteoarthritis: Osteoarthritis is a common degenerative joint disease characterized by the breakdown of cartilage. The aging population, sedentary lifestyles, and the rising incidence of obesity contribute to the increasing prevalence of osteoarthritis. Viscosupplementation, which involves injecting hyaluronic acid into the affected joint, provides pain relief and improved joint mobility, thereby driving the demand for viscosupplementation products.
• Rising Demand for Non-Surgical Treatment Options: Many individuals with osteoarthritis prefer non-surgical treatment options before considering surgical interventions. Viscosupplementation offers a non-invasive and minimally invasive approach to managing osteoarthritis symptoms, such as joint pain and stiffness. The increasing preference for non-surgical treatment options contributes to the growth of the viscosupplementation market.
• Growing Aging Population: The global population is aging, with a significant increase in the number of elderly individuals. As people age, the risk of developing osteoarthritis and other musculoskeletal conditions increases. The growing aging population is a key demographic driver for the viscosupplementation market, as elderly individuals seek effective treatment options to manage joint pain and improve their quality of life.
• Technological Advancements in Viscosupplementation Products: Technological advancements in viscosupplementation products have led to the development of improved formulations with enhanced efficacy and longer-lasting effects. These advancements include the use of cross-linked hyaluronic acid, multi-injection regimens, and innovative delivery systems. The availability of advanced viscosupplementation products contributes to market growth.
• Increasing Awareness and Patient Education: Growing awareness of osteoarthritis, its symptoms, and the available treatment options has led to an increased demand for viscosupplementation. Patient education initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies have played a crucial role in raising awareness about viscosupplementation as a viable treatment option for osteoarthritis.
• Favorable Reimbursement Policies: Reimbursement policies and coverage for viscosupplementation procedures vary across different regions and healthcare systems. Favorable reimbursement policies, particularly in developed countries, can significantly impact the adoption of viscosupplementation treatments. Improved reimbursement coverage for viscosupplementation procedures can drive market growth by making the treatment more accessible to patients.
• Research and Development Activities: Ongoing research and development efforts in the field of viscosupplementation aim to improve the understanding of osteoarthritis pathophysiology, optimize treatment protocols, and develop novel viscosupplementation products. These research activities contribute to the growth of the viscosupplementation market by expanding the knowledge base and driving innovation in treatment options.
• Strategic Collaborations and Partnerships: Collaborations and partnerships between pharmaceutical companies, medical device manufacturers, and healthcare providers play a crucial role in expanding the reach and availability of viscosupplementation products. These collaborations help in the development, marketing, and distribution of viscosupplementation treatments, driving market growth.

Future Opportunities Shaping the Viscosupplementation Market’s Evolution:

The viscosupplementation market offers significant opportunities due to the increasing global burden of osteoarthritis and the rising demand for non-surgical treatment options. With aging populations in regions like North America, Europe, and Asia-Pacific, the patient pool for viscosupplementation is expanding rapidly. There is also a growing trend of patients seeking early intervention therapies to delay or avoid costly joint replacement surgeries, creating opportunities for manufacturers to position viscosupplementation as a first-line treatment for knee and hip osteoarthritis. Moreover, the rising incidence of obesity and sports-related injuries worldwide is driving demand for joint pain management solutions, further boosting market potential.

Another major opportunity lies in product innovation and geographic expansion. The development of next-generation hyaluronic acid formulations—such as extended-release, cross-linked, and combination therapies with corticosteroids or platelet-rich plasma (PRP)—presents avenues for differentiation and premium pricing. Additionally, emerging economies with growing healthcare infrastructure, such as India, China, and Brazil, offer untapped markets with increasing patient awareness and affordability. Companies that focus on cost-effective single-injection solutions, enhanced distribution networks, and strategic collaborations with healthcare providers can capture a larger share of this expanding market. As reimbursement policies improve and clinical evidence supporting viscosupplementation grows, the market is well-positioned for sustained growth in the coming years.

Market Insights:

The global viscosupplementation market is bifurcated into product, application, end-use, and geography. On the basis of product, the market is further segmented into single injection, three injection, and five injection. The three injection segment is accounted to hold the largest revenue share in 2024 due to the increasing adoption of the product and the large-scale availability of the product. In contrast, the single injection segment is expected to grow at a significant growth rate over the forecast period due to the fewer side effects, reduced hospital visits, and shorter regimens.

The viscosupplementation comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2025 to 2030. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

Viscosupplementation Market Segmentation:

By Product:

• Single Injection
• Three Injection
• Five Injection

By Application:

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis

By End-Use:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage: Asia Pacific Dominated the Viscosupplementation Market

Geographically, the Asia Pacific dominated the global viscosupplementation market in 2024 and expected to maintain its dominance over the forecast period. The market growth is attributed to the improved healthcare infrastructure in emerging economies such as China, Japan, and India. Furthermore, the rising awareness regarding viscosupplementation and the increasing demand for non-surgical procedures are projected to propel the market growth. Moreover, the growing geriatric population and changing lifestyle is anticipated to fuel the market growth over the forecast period in the Asia Pacific.

Competition Assessment:

Some of the major players operating in the global viscosupplementation market are Sanofi, Anika Therapeutics, Inc., Seikagaku Corporation, Zimmer Holdings Inc., and Bioventus. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Sanofi
• Anika Therapeutics, Inc.
• Seikagaku Corporation
• Zimmer Holdings Inc.
• Bioventus
• Ferring B.V.
• Lifecore Biomedical, LLC
• LG Life Sciences Ltd.
• Salix Pharmaceuticals, Inc.
• Fidia Farmaceutici S.p.A.

Key Questions Answered by Viscosupplementation Market Report

• Global viscosupplementation market forecasts from 2025-2030
• Regional viscosupplementation market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the aforementioned regions
• Viscosupplementation submarket forecasts from 2025-2030 covering the market by product, by application, by end-use, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market